A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Alentis Therapeutics AG
Alentis Therapeutics AG
Mayo Clinic
Neonc Technologies, Inc.
Ocellaris Pharma, Inc.
Inhibrx Biosciences, Inc
Tanabe Pharma America, Inc.
ITM Oncologics GmbH
Incyte Corporation
NuCana plc
OncoC4, Inc.
Aprea Therapeutics
Sarcoma Oncology Research Center, LLC
PureTech
Cybrexa Therapeutics
Salubris Biotherapeutics Inc
AstraZeneca
NextCure, Inc.
Gritstone bio, Inc.
Beijing InnoCare Pharma Tech Co., Ltd.
Nektar Therapeutics
Institut Bergonié
Incyte Corporation
Incyte Corporation
Incyte Corporation
Eli Lilly and Company